005500 — Samjin Pharmaceutical Co Share Price
0.000.00%
Last trade - 00:00- KR₩217bn
- KR₩335bn
- KR₩308bn
- 80
- 84
- 68
- 92
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 10.75 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -37.34% | ||
| Dividend Yield (f) | 4.68% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.83 | ||
| Price to Tang. Book | 0.91 | ||
| Price to Free Cashflow | 11 | ||
| Price to Sales | 0.71 | ||
| EV to EBITDA | 6.87 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 11.85% | ||
| Return on Equity | 14.89% | ||
| Operating Margin | 10.22% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 235,164.89 | 250,070.36 | 274,031.81 | 292,128.53 | 308,349.93 | 321,600 | 338,700 | 4.97% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +133.1 | -0.05 | -26.71 | -11.61 | +115.45 | -48.67 | +10.04 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Samjin Pharmaceuticals co., LTD. is a Korea-based company mainly engaged in the manufacture of pharmaceutical products. The Company’s products include antipyretics, analgesics, antiphlogistic agents, osteoarthritis agents, osteopathic agents, antihistaminic agents, circulatory system drugs, gastrointestinal agents, osteoporosis treatments, hepatic disease agents, respiratory agents, antibiotics agents, detoxifying agents, antifungal agents, antineoplastic agents and others. Its products are provided in the forms of tablets, injections, capsules and others. It distributes its products to the hospitals and drugstores. The Company supplies its products within domestic market and to overseas markets.
Directors
- Ui Hwan Cho CCH (71)
- Seung Ju Choi CCH (71)
- Yong Ju Choi CCE (61)
- Hong Sun Jang CCE (62)
- Gyeong Ho Cheon MDR (58)
- Yik Ju Choi MDR (64)
- Hyeon Nam Myung MDR (53)
- Hui Jong Shin MDR (61)
- Tae Seop Shin OTH (57)
- Gap Jin Lee OTH (56)
- Jong Mu Woo OTH (55)
- Seong Su Lee DRC (72)
- Yeong Wuk Choi NID (54)
- Wan Gyun Hwang NID (57)
- Yil Hyeok Kim NID (80)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 18th, 1968
- Public Since
- June 18th, 1988
- No. of Shareholders
- 11,451
- No. of Employees
- 809
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 12,257,775
- Address
- 121, Wausan-ro, Mapo-gu, SEOUL, 04054
- Web
- https://www.samjinpharm.co.kr/
- Phone
- +82 231400700
- Auditors
- Hanwool Accounting
Upcoming Events for 005500
Q2 2025 Samjin Pharmaceutical Co Ltd Earnings Release
Similar to 005500
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
What is the Samjin Pharmaceutical Co share price?
As of Today at 23:03 UTC, shares in Samjin Pharmaceutical Co are trading at KR₩17,780. This share price information is delayed by 15 minutes.
How has the Samjin Pharmaceutical Co share price performed this year?
Shares in Samjin Pharmaceutical Co last closed at KR₩17,780 and the price had moved by -9.91% over the past 365 days. In terms of relative price strength the Samjin Pharmaceutical Co share price has underperformed the FTSE Developed Asia Pacific Index by -8.89% over the past year.
What are the analyst and broker recommendations for Samjin Pharmaceutical Co?
The overall consensus recommendation for Samjin Pharmaceutical Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Samjin Pharmaceutical Co dividend yield?
The Samjin Pharmaceutical Co dividend yield is 4.5% based on the trailing twelve month period.
Does Samjin Pharmaceutical Co pay a dividend?
Last year, Samjin Pharmaceutical Co paid a total dividend of KR₩800, and it currently has a trailing dividend yield of 4.5%. We do not have any data on when Samjin Pharmaceutical Co is to next pay dividends.
When does Samjin Pharmaceutical Co next pay dividends?
We do not have data on when Samjin Pharmaceutical Co is to next pay dividends. The historic dividend yield on Samjin Pharmaceutical Co shares is currently 4.5%.
How do I buy Samjin Pharmaceutical Co shares?
To buy shares in Samjin Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Samjin Pharmaceutical Co?
As of the previous close price of KR₩17,780, shares in Samjin Pharmaceutical Co had a market capitalisation of KR₩217bn.
Where are Samjin Pharmaceutical Co shares listed?
Here are the trading details for Samjin Pharmaceutical Co:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 005500
What kind of share is Samjin Pharmaceutical Co?
Based on an overall assessment of its quality, value and momentum Samjin Pharmaceutical Co is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Samjin Pharmaceutical Co share price forecast for 2025?
The analyst consensus target price for shares in Samjin Pharmaceutical Co is KR₩24,095. That is 35.52% above the last closing price of KR₩17,780.
Analysts covering Samjin Pharmaceutical Co currently have a consensus Earnings Per Share (EPS) forecast of KR₩1,603 for the next financial year.
Find out moreWhat is the trend in the Samjin Pharmaceutical Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Samjin Pharmaceutical Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +4.55%.
As of the last closing price of KR₩17,780, shares in Samjin Pharmaceutical Co were trading -2.64% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Samjin Pharmaceutical Co PE Ratio?
The Samjin Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is 10.75. The shares last closed at KR₩17,780.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Samjin Pharmaceutical Co?
Samjin Pharmaceutical Co's management team is headed by:
- Ui Hwan Cho - CCH
- Seung Ju Choi - CCH
- Yong Ju Choi - CCE
- Hong Sun Jang - CCE
- Gyeong Ho Cheon - MDR
- Yik Ju Choi - MDR
- Hyeon Nam Myung - MDR
- Hui Jong Shin - MDR
- Tae Seop Shin - OTH
- Gap Jin Lee - OTH
- Jong Mu Woo - OTH
- Seong Su Lee - DRC
- Yeong Wuk Choi - NID
- Wan Gyun Hwang - NID
- Yil Hyeok Kim - NID